Long-Term Outcomes After Chemoradiotherapy and Surgery for Superior Sulcus Tumors.
Clinical outcomes
Non–small cell lung cancer
Pancoast tumor
Pathologic response
Superior sulcus
Trimodality therapy
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
24
10
2022
revised:
14
01
2023
accepted:
31
01
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Superior sulcus tumors (SSTs) are uncommon, and their anatomical location can make treatment challenging. We analyzed late outcomes of patients with SST treated with concurrent chemoradiotherapy followed by surgical resection (trimodality) in a single tertiary institution. Patients with non-small cell SSTs, who underwent trimodality therapy between 2002 and 2017, were selected from a prospective institutional surgical database. Patients were uniformly staged with 18F-fluorodeoxyglucose-positron emission tomography, computed tomography scan of the chest and upper abdomen, and brain imaging. Patients undergoing resection of the lung plus chest wall were grouped as limited SST and those needing extensive resections (e.g., including the vertebral body) as extended SST. Kaplan-Meier survival analysis was performed to determine difference in survival. Multivariate Cox regression was used to identify prognostic factors. A total of 123 patients were identified with a median follow-up of 4.9 years (interquartile range: 1.6-8.9 y). The 90-day postoperative mortality and morbidity (Clavien-Dindo grades III-V) were 6.5% and 21.1%, respectively. Patients with a radical resection (R0: 92.7%) had better survival ( In patients with SST, trimodality resulted in a 10-year estimated OS and disease-free survival of 48.1% and 42.6%, respectively, which were improved after radical resection (R0) and major pathologic response. Survival for limited and extended resections was comparable, and distant relapse was the main pattern of failure. Better systemic treatments are therefore needed.
Identifiants
pubmed: 36969550
doi: 10.1016/j.jtocrr.2023.100475
pii: S2666-3643(23)00014-0
pmc: PMC10031478
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100475Informations de copyright
© 2023 The Authors.
Références
Lung Cancer. 2021 Nov;161:42-48
pubmed: 34509720
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2007 Jan 20;25(3):313-8
pubmed: 17235046
BMC Cancer. 2020 Aug 14;20(1):764
pubmed: 32795284
Lancet. 2021 Oct 9;398(10308):1344-1357
pubmed: 34555333
Interact Cardiovasc Thorac Surg. 2013 Jan;16(1):44-8
pubmed: 23049081
Ann Thorac Surg. 2017 Apr;103(4):1070-1075
pubmed: 28110809
J Clin Oncol. 2008 Feb 1;26(4):644-9
pubmed: 18235125
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Jpn J Clin Oncol. 2022 Apr 6;52(4):383-387
pubmed: 34999817
J Clin Oncol. 2022 Apr 20;40(12):1301-1311
pubmed: 35108059
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
J Clin Oncol. 2016 Mar 20;34(9):953-62
pubmed: 26811519
Gen Thorac Cardiovasc Surg. 2022 Sep;70(9):812-817
pubmed: 35304712
Ann Oncol. 2021 Dec;32(12):1637-1642
pubmed: 34481037
Ther Adv Med Oncol. 2018 Oct 05;10:1758835918804150
pubmed: 30305851
Lung Cancer. 2003 Dec;42 Suppl 1:S9-14
pubmed: 14708516